zinc finger protein 462Genealiases: WSKA · ZFPIP · Zfp462
Q-omics provides the consensus-scored ZNF462 profile across patient tissues and cancer cell-line models. ZNF462 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF462 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, ZNF462 RNA expression shows 20,513 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KIRP, and ACC as cancer lineages where ZNF462 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF462 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF462 survival associations across molecular data types. ZNF462 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF462 RNA expression–survival associations across cancer types. High ZNF462 expression shows unfavorable associations in ACC, BLCA and HNSC, but favorable associations in KIRC, SCLC and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF462 RNA expression.
This table summarizes ZNF462 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF462. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF462 shows lower tumor expression in KICH, BRCA and UCEC and higher tumor expression in KIRP, KIRC and PAAD. The KIRP box plot shows higher ZNF462 RNA expression in tumor versus normal tissue (log2 FC = +1.069, t-test p < 0.001).
This table shows molecular features associated with ZNF462 in patient tissues and cancer cell lines. In patient samples, ZNF462 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF462 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
